KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Adaptive Biotechnologies (ADPT) Equity Average (2019 - 2025)

Historic Equity Average for Adaptive Biotechnologies (ADPT) over the last 7 years, with Q3 2025 value amounting to $192.1 million.

  • Adaptive Biotechnologies' Equity Average fell 1745.34% to $192.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $192.1 million, marking a year-over-year decrease of 1745.34%. This contributed to the annual value of $255.6 million for FY2024, which is 3384.26% down from last year.
  • As of Q3 2025, Adaptive Biotechnologies' Equity Average stood at $192.1 million, which was down 1745.34% from $185.1 million recorded in Q2 2025.
  • In the past 5 years, Adaptive Biotechnologies' Equity Average registered a high of $734.5 million during Q1 2021, and its lowest value of $185.1 million during Q2 2025.
  • Over the past 5 years, Adaptive Biotechnologies' median Equity Average value was $410.0 million (recorded in 2023), while the average stood at $419.8 million.
  • As far as peak fluctuations go, Adaptive Biotechnologies' Equity Average soared by 3120.89% in 2021, and later plummeted by 3858.6% in 2024.
  • Quarter analysis of 5 years shows Adaptive Biotechnologies' Equity Average stood at $627.8 million in 2021, then fell by 24.18% to $476.0 million in 2022, then dropped by 29.61% to $335.1 million in 2023, then crashed by 36.36% to $213.2 million in 2024, then dropped by 9.93% to $192.1 million in 2025.
  • Its last three reported values are $192.1 million in Q3 2025, $185.1 million for Q2 2025, and $196.6 million during Q1 2025.